Inflazome's NLRP3 inhibitor drugs reach phase II in clinical trials

Inflazome's NLRP3 inhibitor drugs reach phase II in clinical trials

12 Aug 20 admin Discovery 0 Comments

The Inflammasome lab is thrilled that NLRP3 inflammasome inhibitors are now in Phase II in clinical trials with Inflazome.

It is exciting to see that our contributions to the development and understanding of small molecule inflammasome inhibitors are moving towards making a real difference to human health and wellbeing!

Posted by admin

ABOUT Inflammasome Lab

Inflammasome Lab is a group of researchers led by Prof Kate Schroder at the Institute for Molecular Bioscience, The University of Queensland.
We seek to unravel the secrets of inflammasomes – protein complexes at the heart of inflammation and disease – to allow for new therapies to fight human diseases.